NASDAQ:QNRX Quoin Pharmaceuticals (QNRX) Stock Price, News & Analysis $0.61 -0.01 (-1.62%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.59▼$0.6550-Day Range$0.58▼$0.7852-Week Range$0.57▼$8.28Volume91,880 shsAverage Volume294,352 shsMarket Capitalization$2.42 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Quoin Pharmaceuticals alerts: Email Address Quoin Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside557.0% Upside$4.00 Price TargetShort InterestHealthy0.15% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 3 Articles This WeekInsider TradingSelling Shares$217 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.51) to ($0.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.51 out of 5 stars 3.5 Analyst's Opinion Consensus RatingQuoin Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageQuoin Pharmaceuticals has received no research coverage in the past 90 days.Read more about Quoin Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.15% of the outstanding shares of Quoin Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverQuoin Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quoin Pharmaceuticals has recently decreased by 52.71%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldQuoin Pharmaceuticals does not currently pay a dividend.Dividend GrowthQuoin Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for QNRX. Previous Next 3.6 News and Social Media Coverage News SentimentQuoin Pharmaceuticals has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Quoin Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest5 people have searched for QNRX on MarketBeat in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Quoin Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $217.00 in company stock.Percentage Held by InsidersOnly 3.30% of the stock of Quoin Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 8.63% of the stock of Quoin Pharmaceuticals is held by institutions.Read more about Quoin Pharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Quoin Pharmaceuticals are expected to grow in the coming year, from ($3.51) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quoin Pharmaceuticals is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quoin Pharmaceuticals is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuoin Pharmaceuticals has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Quoin Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Quoin Pharmaceuticals Stock (NASDAQ:QNRX)Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.Read More QNRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QNRX Stock News HeadlinesJuly 26 at 1:12 AM | americanbankingnews.comContrasting Quoin Pharmaceuticals (NASDAQ:QNRX) & Evoke Pharma (NASDAQ:EVOK)June 25, 2024 | globenewswire.comQuoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National ConferenceJuly 26, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."June 12, 2024 | globenewswire.comQuoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), IrelandMay 22, 2024 | finance.yahoo.comQNRX: Protocol Modifications Potentially Accelerate, Expand QRX003 ApprovalsMay 9, 2024 | msn.comQuoin Pharmaceuticals Non-GAAP EPS of -$1.11 misses by $0.70May 9, 2024 | finance.yahoo.comQuoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial ResultsMay 9, 2024 | globenewswire.comQuoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial ResultsJuly 26, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."May 2, 2024 | globenewswire.comQuoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024March 16, 2024 | seekingalpha.comQuoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | markets.businessinsider.comMaxim Group Maintains Buy Rating for Quoin Pharmaceuticals: Here's What You Need To KnowMarch 15, 2024 | finance.yahoo.comQuoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | finanznachrichten.deQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial ResultsMarch 14, 2024 | benzinga.comQuoin Pharmaceuticals: Q4 Earnings InsightsMarch 13, 2024 | globenewswire.comQuoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial ResultsMarch 7, 2024 | msn.comWhy Quoin Pharmaceuticals (QNRX) Shares Are NosedivingMarch 7, 2024 | globenewswire.comQuoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ETSee More Headlines Receive QNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quoin Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:QNRX CUSIPN/A CIK1671502 Webquoinpharma.com Phone(703) 980-4182Fax972-9767-8750Employees4Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+557.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($7.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,690,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-107.57% Return on Assets-56.01% Debt Debt-to-Equity RatioN/A Current Ratio3.61 Quick Ratio3.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.74 per share Price / Book0.11Miscellaneous Outstanding Shares3,980,000Free Float3,849,000Market Cap$2.42 million OptionableNot Optionable Beta1.97 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Michael Myers Ph.D. (Age 62)Co-Founder, CEO & Chairman Comp: $661.8kMs. Denise Carter (Age 55)Co-Founder, COO & Director Comp: $537.8kMr. Gordon Bruce Dunn J.D. (Age 60)Chief Financial Officer Comp: $394.2kKey CompetitorsAgile TherapeuticsNASDAQ:AGRXAeterna ZentarisNASDAQ:AEZSPurple BiotechNASDAQ:PPBTMolecular TemplatesNASDAQ:MTEMCyclerion TherapeuticsNASDAQ:CYCNView All CompetitorsInsiders & InstitutionsDennis LangerSold 297 sharesTotal: $216.81 ($0.73/share)Virtu Financial LLCBought 30,749 shares on 5/20/2024Ownership: 0.773%View All Insider TransactionsView All Institutional Transactions QNRX Stock Analysis - Frequently Asked Questions How have QNRX shares performed this year? Quoin Pharmaceuticals' stock was trading at $4.91 on January 1st, 2024. Since then, QNRX shares have decreased by 87.6% and is now trading at $0.6088. View the best growth stocks for 2024 here. How were Quoin Pharmaceuticals' earnings last quarter? Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) issued its quarterly earnings results on Thursday, May, 9th. The company reported ($1.11) earnings per share (EPS) for the quarter. When did Quoin Pharmaceuticals' stock split? Quoin Pharmaceuticals's stock reverse split before market open on Monday, July 17th 2023. The 1-12 reverse split was announced on Monday, July 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Quoin Pharmaceuticals? Shares of QNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:QNRX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quoin Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quoin Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.